Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 13

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 13
---

Entertainment, Inc. On October 14, 2008, the Company merged with OC Beverage, Inc. a Nevada corporation, a manufacturer of beverages,
and on October 31, 2008 it subsequently changed its name to OC Beverages, Inc. It ceased operations as a manufacturer of beverages in
2010. On June 22, 2020, the Company formed a wholly owned Israeli subsidiary called Revium Recovery Ltd. On December 4, 2020, the Company
changed its name to Revium Recovery Inc.

On December 17, 2024, the Company completed
the redomicile from the State of Delaware to the State of Nevada by conversion (the “Reincorporation”), pursuant to the Plan
of Conversion dated December 16, 2024. As a result of the Reincorporation, the Company ceased its business existence as a Delaware corporation
and continued its business existence as a Nevada corporation under the name “Revium Rx” succeeding all our rights, assets,
liabilities and obligations, except that our affairs ceased to be governed by the Delaware General Corporation Law, the Certificate of
Incorporation, as amended, and became subject to the Nevada Revised Statutes, Articles of Incorporation and our new bylaws. The Reincorporation
did not change the number of the authorized shares of the Company, its par value, or its issued and outstanding shares.

<div align='center'>1</div>

Share Exchange Agreement

On July 23, 2024, we consummated the share exchange
transaction (the “Share Exchange”) contemplated by the Stock Exchange Agreement, dated November 14, 2023 (the “Share
Exchange Agreement”), by and among the Company, LipoVation Ltd., a company organized under the laws of the State of Israel (“LipoVation”),
and all shareholders of LipoVation (the “LipoVation Shareholders”). As a result of the consummation of the Share Exchange,
LipoVation became a wholly owned subsidiary of the Company. At such date, the shareholders of LipoVation contributed all of their shareholdings
in LipoVation in exchange for 23,171,642 shares of the Company’s Common Stock (the “Exchange Shares”) with each LipoVation
Shareholder receiving a pro rata portion of the Exchange Shares based on their ownership in LipoVation. The Exchange Shares represented
approximately 40% of the issued